Last week, we made a commitment: to tell you what the research on muscadine actually shows, including where it stops. This week, we’re following through.
The Banini study is the most directly relevant published human trial on muscadine and metabolic markers. Here’s exactly what it was, what it found, and where its limits lie.
The Study at a Glance
Banini AE, Boyd LC, Allen JC, Allen HG, and Sauls DL. “Muscadine grape products intake, diet and blood constituents of non-diabetic and type 2 diabetic subjects.” Nutrition, 2006; 22(11–12):1137–1145. North Carolina State University.
| Element | Detail |
| Study | Banini AE et al., Nutrition 2006; 22(11–12):1137–1145 |
| Institution | North Carolina State University, Raleigh, NC |
| Design | Non-randomized, non-blinded dietary intervention; 28 days |
| Population | Type 2 diabetic subjects (assigned to MJ, MW, or Dz-W) and non-diabetic subjects (juice only) |
| Intervention | 150 mL/day of muscadine grape juice (MJ), muscadine grape wine (MW), or dealcoholized muscadine grape wine (Dz-W) with meals |
| Primary outcomes | Glycemic indices, blood glucose, insulin, glycated hemoglobin (HbA1c), lipid profile, blood constituents |
| Key findings | Diabetics given MW and Dz-W showed lower blood glucose, insulin, and HbA1c vs. diabetics given MJ. Dz-W group: fasting blood insulin reduced; glucose:insulin ratio improved from 8.5 to 13.1. MJ and MW did not differ in fasting glucose, insulin, or HbA1c in the non-diabetic group. |
| Study limitation | Non-diabetic group received juice only — no wine or Dz-W arm. No placebo control. Cannot compare non-diabetic outcomes to diabetic outcomes across product types. |
What It Found
The most meaningful findings came from Type 2 diabetic subjects assigned to muscadine wine and dealcoholized muscadine wine. Compared with diabetics given muscadine juice, those groups had lower blood glucose, insulin, and glycated hemoglobin levels over the 28-day period.
The dealcoholized wine group — the arm most relevant to a supplement context, since alcohol is removed — showed a specific improvement in fasting blood insulin levels. The fasting blood glucose-to-insulin ratio rose from 8.5 to 13.1 over the intervention period. The researchers noted that a ratio below 7 is considered predictive of insulin resistance; the published data showed movement away from that threshold in the T2D group over 28 days.
These are real findings from a real peer-reviewed study in a population where metabolic markers matter most.
What It Doesn’t Show
Here is where we’re going to be direct, because this is where ingredient marketing most often goes wrong.
The non-diabetic subjects in this study received only muscadine juice. There was no wine or dealcoholized wine arm for healthy subjects, and no placebo control for that group. You cannot draw conclusions about muscadine’s effect on healthy adults’ metabolic markers from this study design.
The intervention used whole beverage forms — 150 mL of juice, wine, or dealcoholized wine per day. This is not the same as a standardized extract powder or capsule. The polyphenol dose, bioavailability, and matrix context of a beverage differ from those of an encapsulated ingredient. Extrapolating these findings to a capsule product requires additional research.
28 days is a short intervention window. These findings are a signal worth taking seriously, not a conclusion about long-term metabolic outcomes.
This was not a randomized, blinded, placebo-controlled trial — the design most likely to produce generalizable results. The findings are meaningful and peer-reviewed, but the study design has limitations that should inform how confidently you cite it.
Why This Still Matters for Formulators
Here’s why it still matters.
Many metabolic health ingredients have limited or no peer-reviewed human research. Their evidence base often rests on mechanistic rationale — in vitro studies showing that a compound interacts with a relevant pathway in cell culture, which is a long way from a human outcome. The Banini study, with its clearly stated limitations, still places muscadine in a category most competing ingredients cannot enter.
This research also holds up when a retailer or practitioner asks the right question — not “what does your marketing say?” but “what does your best published human study actually show?” We can answer that with a citation, a methodology, and an honest account of what was and wasn’t found. That’s a more defensible position than most suppliers in this category can offer.
The Right Application
Given what this study used, the MPC ingredient form most directly relevant to this research context is Muscadine Juice Concentrate — the beverage-form polyphenol delivery that most closely mirrors what was studied. It is appropriate for liquid supplement applications and functional beverage formulations.
Muscadine Skin/Seed Powder — our encapsulated ingredient form — provides the same phytochemical profile in capsule or tablet applications. It is a non-soluble powder, appropriate for encapsulation, not for beverage blending. The phytochemical case for that form is strong; the direct clinical link to the Banini study is more attenuated, and we will not overstate it.
If your R&D team wants to review the full Banini citation, methodology, and published abstract, contact us and we’ll send them directly. We’d rather put the actual study in front of your team than a polished summary.
Next Week
The series moves to June’s theme: Skin Health / Beauty From Within. We’ll cover Muscadine Seed Oil and Skin Extract — two ingredients with a genuinely differentiated story for cosmetic formulators and ingestible beauty brands. If you want to be ready for that conversation, visit muscadineproducts.com to request a sample or technical documentation.
| These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Research references are cited for informational and educational purposes. The Banini study was conducted in a Type 2 diabetic population using whole beverage forms of muscadine; findings should not be generalized to healthy populations or encapsulated ingredient forms without additional research. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products. Muscadine Products Corporation • Wray, Georgia • muscadineproducts.com |
